Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson eRLEADA (apalutamide) — Worldwide operational (constant-currency) growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2025
17.2%
Period ended Dec 28, 2025
Change on a year earlier
-10.1 pts
27.3% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ERLEADA (apalutamide) — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 17.2% | -10.1 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 27.3% | -0.2 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | 27.5% | -25.5 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| FY2022 | Jan 1, 2023 | 53.0% | -15.7 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | 68.7% | – | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
Breakdown
What makes up erleada (apalutamide) — worldwide operational (constant-currency) growth yoy (%)
Cite this data
StockData. (2026). Johnson & Johnson ERLEADA (apalutamide) — Worldwide operational (constant-currency) growth YoY (%) (%), annual FY2021–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_erleada_ops_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.